Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biomarkers in Oncology | Access & Reimbursement | US | Malignant Melanoma, Colorectal Cancer, Ovarian Cancer | US

Login to access report north_east
Contact sales account_box

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant melanoma, colorectal cancer, and ovarian cancer. When incorporated into standard clinical care, biomarker-driven therapies offer specific subpopulations of patients the potential for higher response rates and improved survival, albeit often at a high price. We explore the drivers of and barriers to the use of biomarker-based therapies and the impact of reimbursement policies on the use of these therapies. We also evaluate surveyed medical oncologists’ and surveyed payers’ prescriptions of emerging biomarker-driven therapies to treat these solid-tumor indications.

 

QUESTIONS ANSWERED

· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in malignant melanoma, colorectal cancer, and ovarian cancer? What restrictions do they impose?

· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

· What impact do reimbursement and access have on oncologists’ decisions to prescribe biomarker-driven therapies?

· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

 

GEOGRAPHY: United States.

PRIMARY RESEARCH: Survey of 101 U.S. medical oncologists and 31 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).

KEY DRUGS COVERED: Avastin, Erbitux, Vectibix, Opdivo, Keytruda, Yervoy, Zelboraf, Tafinlar, Mekinist, Cotellic, Braftovi, Mektovi, Lynparza, Zejula, Rubraca

CONTENT HIGHLIGHTS:

  • Executive Summary
  • Reimbursement
  • Access and prescribing.
  • Special topic: Market Access Outlook for biomarkers testing
  • Opportunities and challenges for emerging therapies.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east